Overview
Traditionally, microbial cell cultures have been the preferred choice for the production of the variety of biologics, including peptide therapeutics and certain low molecular weight proteins (insulin) and cytokines. Till date, over 60% of recombinant proteins used for therapeutic purposes, are estimated to be produced using microbial expression systems, primarily Escherichia coli. In fact, more than 70 biologics approved by various regulatory authorities, worldwide, are manufactured using microbial fermentation. It is worth highlighting that the growing interest in certain novel biologics, such as antibody fragments and plasmid DNA (with potential application areas in cell and gene therapies, and DNA vaccines), has led to a substantial increase in demand for microbial system-based production. Furthermore, evolutionary advances in manufacturing technologies have resulted in a renewed interest from drug developers in using microbial platforms for the production of complex biologics.
Given the inherent complexities in the development and production of biologics, drug developers have demonstrated the preference to outsource parts of their microbial manufacturing operations, as well. In fact, there has been a rise in the outsourcing activity in relation to microbial fermentation since 2017. Presently, the microbial contract biomanufacturing market features a mix of small, mid-sized and large players, offering end-to-end solutions, ranging from early stage process development to clinical and commercial scale manufacturing and regulatory filing. Despite this being a fairly well-established domain, more than 25 new contract microbial fermentation companies have been established over the last decade. Therefore, in order to remain competitive, CMOs/CDMOs have begun active in acquiring cutting-edge fermentation technologies and investing in the development of the necessary capacity to support the growing demand for novel biologics. It is also worth highlighting that the COVID-19 pandemic is also likely to create significant business opportunities for microbial CMOs as innovator companies are expected to seek support in manufacturing of potential vaccines and other therapeutic modalities. In the long term, we are led to believe that the contract services market catering to this segment of the biopharma industry is anticipated to witness substantial growth in the coming years.
Scope of the Report
The “Microbial Contract Biomanufacturing Market, 2020-2030” report features an extensive study of the current market landscape and future opportunities associated with the microbial contract biomanufacturing market. The study also features a detailed analysis of key drivers and trends related to this evolving domain.
Amongst other elements, the report includes:
- A detailed review of the current landscape of companies offering contract manufacturing services for biologics, using microbial expression systems, along with information on their year of establishment, company size, location of headquarters, number and location of their production facilities, scale of operation (preclinical, clinical and commercial), type of biologic(s) manufactured (peptides/proteins, antibodies, vaccines, biosimilars, oligonucleotides, plasmid DNA and others), type of microbial expression system(s) used (bacterial, yeast and others), type of fermenter(s) employed (single-use fermenters, stainless steel fermenters and others), type of manufacturing service(s) offered (cell banking, process development and characterization, analytical method development and testing, quality assurance and control, scale-up, downstream processing and regulatory support), and regulatory accreditations/certifications received (if any).
- A region-wise, company competitiveness analysis, highlighting key players engaged in microbial based contract manufacturing based on their experience (considering the year of establishment of the firm) and expertise (taking into account their service portfolio, number of different types of biologics manufactured and number of distinct expression system(s) used).
- An analysis of the various partnerships signed within this domain, with a focus on microbial contract biomanufacturing, since 2016, based on several relevant parameters, such as year of partnership, type of partnership model adopted, scale of operation, type of biologic, focus area, therapeutic area, most active players (in terms of number of partnerships signed), and geography. Further, it features a detailed analysis of the various mergers and acquisitions that were carried out in this domain, highlighting the trend in terms of number of players acquired between 2016-2020 (till May), along with the geographical distribution of this activity.
- An elaborate analysis of the various expansion initiatives undertaken by contract manufacturers using microbial expression systems in order to augment their capabilities, over the period 2016-2020 (till May), taking into consideration several relevant parameters, such as year of expansion, type of expansion (capability expansion, capacity expansion, facility expansion and new facility), scale of operation of manufacturing facility, type of biologic and location of manufacturing facility.
- A review of the varied microbial based manufacturing initiatives undertaken by big pharma players (shortlisted from the top 20 pharmaceutical companies as of 2019), highlighting trends across various parameters, such as number of initiatives, year of initiative and type of initiative.
- A detailed proprietary 2×2 representation that was developed to assess the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.
- Elaborate profiles of key players that offer contract biomanufacturing services using microbial expression systems across different geographies, namely North America, Europe and Asia Pacific. Each profile features a brief overview of the company, information related to its service portfolio, manufacturing capabilities and facilities, recent developments and an informed future outlook.
- A discussion on industry affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the evolution of this field. It also includes a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on industry dynamics.
- A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
- An insightful discussion on the impact of COVID-19 outbreak on the overall microbial contract biomanufacturing market, and the key initiatives undertaken by CMOs to combat the challenges posed due to ongoing situation.
One of the key objectives of the report was to estimate the existing market size and the future growth potential within the microbial contract biomanufacturing market. Based on multiple parameters, such as projected growth of the overall microbial biomanufacturing market, cost of goods sold and direct manufacturing costs, we developed informed estimates describing the financial evolution of the market, over the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] type of biologic (proteins, vaccines and others) [B] type of microbial expression system used (bacterial, yeast and others) [C] scale of operation (preclinical/clinical and commercial) [D] end user (small, mid-sized and large/very large), and [E] key geographical regions (North America, Europe and Asia Pacific, Middle East and North Africa and Latin America). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry.
The report features detailed transcripts of interviews held with the following industry stakeholders:
- Gaurav Kaushik (Chief Executive Officer and Managing Director, Meteoric Biopharmaceuticals)
- Debbie Pinkston (Vice President, Sales and Business Development, List Biological Laboratories)
- Andrea Conforto (Sales and Marketing, Bioservices Director, Olon)
- Max Rossetto (General Manager, Business Development, Luina Bio)
- Rob van Dijk (Business Development Manager, WACKER Biotech)
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Key Questions Answered
- Who are the leading CMOs with expertise in production of microbial biologics?
- What are the preferred microbial expression systems used in biologic development and manufacturing?
- What are the key microbial fermentation technology platforms?
- Who could be the potential partners for the microbial CMOs?
- What kind of partnership models are commonly adopted by stakeholders engaged in this domain?
- What type of expansion initiatives are being carried out by CMOs in this domain?
- What initiatives are being undertaken by big pharma players in this domain?
- What are the key factors influencing the make (manufacture in-house) versus buy (outsource) decision related to microbial fermentation?
- What are the key trends within the microbial contract biomanufacturing market?
- How is the current and future market opportunity likely to be distributed across key market segments?
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3P Biopharmaceuticals
- 3SBio
- 53Biologics
- AbbVie
- AbbVie Contract Manufacturing
- Adare Pharmaceuticals
- ADL Bionatur Solutions
- ADL BioPharma
- ADM Biopolis
- Advaxis
- Affibody
- Affinity Life Sciences
- AGC Biologics
- Ajinomoto Bio-Pharma Services
- Akers Biosciences
- Akshaya Bio
- Aldevron
- Allergan
- Alliance Protein Laboratories
- Altor BioScience
- Amgen
- AMRI
- Arranta Bio
- AstraZeneca
- Aumgene Biosciences
- AURA Biotechnologies
- Axcellerate Pharma
- BacThera
- Batavia Biosciences
- Bexion Pharmaceuticals
- BIA Separations
- BINEX
- Bio Elpida
- BioCell
- Biological E.
- BioMARC
- Biomay
- Biomeva (Acquired by AGC)
- Bionaturis
- BioProduction by Sekisui
- Biose industrie
- Biosynergy (Europe)
- Bio-Synthesis
- Bio-Technology General
- BioVectra
- Biovian
- BJP Laboratories
- Boehringer Ingelheim
- Boehringer Ingelheim BioXcellence
- Boston Institute of Biotechnology
- Bristol-Myers Squibb
- Capsugel
- Captozyme (Acquired by Arranta Bio)
- Capua BioServices
- Cara Therapeutics
- Cerbios-Pharma
- Charles River Laboratories
- ChemPartner
- CinnaGen
- Citryll
- Clovis Oncology
- Cobra Biologics
- Corden BioChem
- Creative Biolabs
- Cytovance Biologics
- Dyadic International
- EirGenix
- EKF Life Sciences
- Eli Lilly
- Elion Labs
- Emergent BioSolutions
- Enteris BioPharma
- Etinpro
- EuBiologics
- Eucodis Bioscience
- Eurogentec
- Evonik Health Care
- Fermentalg
- Ferring Pharmaceuticals
- Finox
- Fresenius Medical Care
- FUJIFILM Diosynth Biotechnologies
- GE Healthcare
- GenIbet Biopharmaceuticals
- Genome & Company
- GreenPak Biotech
- Griffith University
- GSK Contract Manufacturing
- GT Biopharma
- GTP Technology
- Hansa Biopharma
- Hong Kong Institute of Biotechnology
- Inovio Pharmaceuticals
- Inpac Probiotics
- Jeneil Biotech
- Johnson & Johnson
- Kanda BioTech
- KBI Biopharma
- Keryx Biopharmaceuticals
- KeyBioscience
- LakePharma
- List Biological Laboratories
- LNC Therapeutics
- Lonza
- Luina Bio
- Maine Biotechnology Services
- Menarini Biotech
- Merck
- Merck Millipore
- Meridian Life Science
- Meteoric Biopharmaceuticals
- MicroBiopharm Japan
- Mologic
- Mycenax Biotech
- Nature Technology
- Nebraska Cultures
- NIZO
- Northway Biotechpharma
- Novartis
- Novo Nordisk
- NUMAFERM
- Ology Bioservices
- Olon
- Omeros
- Oncobiologics
- Orbis Biosciences
- Panacea Biotec
- Paragon Bioservices (unit of Catalent Biologics)
- Paras Biopharmaceuticals Finland
- PEPDesign
- Pfizer
- Pfizer CentreOne
- PhaseBio
- Pierre Fabre
- Polpharma Biologics
- Polymun Scientific
- Portola Pharmaceuticals
- Porton Biopharma
- Premas Biotech
- PrEP Biopharm
- ProbioFerm
- Probiotical
- Proteon Therapeutics
- Protexin
- Proventus Bioscience
- PX’Therapeutics
- Quantum Hi-Tech China Biological
- Quay Pharma
- Reliance Life Sciences
- Richter-Helm BioLogics
- Roche
- Sandoz
- Sanofi
- Scientific Protein Laboratories (SPL)
- Scil Proteins Pharma
- Siam Bioscience
- SiliCycle
- Stelis BioSource™ (manufacturing arm of Stelis Biopharma)
- SynCo Bio
- Syngene
- Takara Bio
- Taron Solutions
- The Native Antigen Company
- Therapure Biopharma
- TUBE Biopharmaceuticals
- UAS Labs
- Unique Biotech
- Vectron Biosolutions
- Vestaron
- VGXI
- Vibalogics
- Vigene Biosciences
- VTU Technology
- VxP Biologics
- WACKER Biotech
- Waisman Biomanufacturing
- Winclove Probiotics
- WuXi Biologics
- XL-protein
- Zhejiang Hisun Pharmaceutical
- Zhittya Genesis Medicine
Methodology
LOADING...